Intestinal metabolites predict treatment resistance of patients with depression and anxiety
Abstract Background The impact of the gut microbiota on neuropsychiatric disorders has gained much attention in recent years; however, comprehensive data on the relationship between the gut microbiome and its metabolites and resistance to treatment for depression and anxiety is lacking. Here, we inv...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-02-01
|
| Series: | Gut Pathogens |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13099-024-00601-3 |
| _version_ | 1797274443888721920 |
|---|---|
| author | Juntaro Matsuzaki Shunya Kurokawa Chiaki Iwamoto Katsuma Miyaho Akihiro Takamiya Chiharu Ishii Akiyoshi Hirayama Kenji Sanada Shinji Fukuda Masaru Mimura Taishiro Kishimoto Yoshimasa Saito |
| author_facet | Juntaro Matsuzaki Shunya Kurokawa Chiaki Iwamoto Katsuma Miyaho Akihiro Takamiya Chiharu Ishii Akiyoshi Hirayama Kenji Sanada Shinji Fukuda Masaru Mimura Taishiro Kishimoto Yoshimasa Saito |
| author_sort | Juntaro Matsuzaki |
| collection | DOAJ |
| description | Abstract Background The impact of the gut microbiota on neuropsychiatric disorders has gained much attention in recent years; however, comprehensive data on the relationship between the gut microbiome and its metabolites and resistance to treatment for depression and anxiety is lacking. Here, we investigated intestinal metabolites in patients with depression and anxiety disorders, and their possible roles in treatment resistance. Results We analyzed fecal metabolites and microbiomes in 34 participants with depression and anxiety disorders. Fecal samples were obtained three times for each participant during the treatment. Propensity score matching led us to analyze data from nine treatment responders and nine non-responders, and the results were validated in the residual sample sets. Using elastic net regression analysis, we identified several metabolites, including N-ε-acetyllysine; baseline levels of the former were low in responders (AUC = 0.86; 95% confidence interval, 0.69–1). In addition, fecal levels of N-ε-acetyllysine were negatively associated with the abundance of Odoribacter. N-ε-acetyllysine levels increased as symptoms improved with treatment. Conclusion Fecal N-ε-acetyllysine levels before treatment may be a predictive biomarker of treatment-refractory depression and anxiety. Odoribacter may play a role in the homeostasis of intestinal L-lysine levels. More attention should be paid to the importance of L-lysine metabolism in those with depression and anxiety. |
| first_indexed | 2024-03-07T14:59:23Z |
| format | Article |
| id | doaj.art-61c8b207c5e0478b89942bebb8655c39 |
| institution | Directory Open Access Journal |
| issn | 1757-4749 |
| language | English |
| last_indexed | 2024-03-07T14:59:23Z |
| publishDate | 2024-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Gut Pathogens |
| spelling | doaj.art-61c8b207c5e0478b89942bebb8655c392024-03-05T19:15:45ZengBMCGut Pathogens1757-47492024-02-0116111210.1186/s13099-024-00601-3Intestinal metabolites predict treatment resistance of patients with depression and anxietyJuntaro Matsuzaki0Shunya Kurokawa1Chiaki Iwamoto2Katsuma Miyaho3Akihiro Takamiya4Chiharu Ishii5Akiyoshi Hirayama6Kenji Sanada7Shinji Fukuda8Masaru Mimura9Taishiro Kishimoto10Yoshimasa Saito11Division of Pharmacotherapeutics, Keio University Faculty of PharmacyHills Joint Research Laboratory for Future Preventive Medicine and Wellness, Keio University School of MedicineDivision of Pharmacotherapeutics, Keio University Faculty of PharmacyDepartment of Psychiatry, Showa University Graduate School of MedicineHills Joint Research Laboratory for Future Preventive Medicine and Wellness, Keio University School of MedicineInstitute for Advanced Biosciences, Keio UniversityInstitute for Advanced Biosciences, Keio UniversityDepartment of Psychiatry, Showa University Graduate School of MedicineInstitute for Advanced Biosciences, Keio UniversityDepartment of Neuropsychiatry, Keio University School of MedicineHills Joint Research Laboratory for Future Preventive Medicine and Wellness, Keio University School of MedicineDivision of Pharmacotherapeutics, Keio University Faculty of PharmacyAbstract Background The impact of the gut microbiota on neuropsychiatric disorders has gained much attention in recent years; however, comprehensive data on the relationship between the gut microbiome and its metabolites and resistance to treatment for depression and anxiety is lacking. Here, we investigated intestinal metabolites in patients with depression and anxiety disorders, and their possible roles in treatment resistance. Results We analyzed fecal metabolites and microbiomes in 34 participants with depression and anxiety disorders. Fecal samples were obtained three times for each participant during the treatment. Propensity score matching led us to analyze data from nine treatment responders and nine non-responders, and the results were validated in the residual sample sets. Using elastic net regression analysis, we identified several metabolites, including N-ε-acetyllysine; baseline levels of the former were low in responders (AUC = 0.86; 95% confidence interval, 0.69–1). In addition, fecal levels of N-ε-acetyllysine were negatively associated with the abundance of Odoribacter. N-ε-acetyllysine levels increased as symptoms improved with treatment. Conclusion Fecal N-ε-acetyllysine levels before treatment may be a predictive biomarker of treatment-refractory depression and anxiety. Odoribacter may play a role in the homeostasis of intestinal L-lysine levels. More attention should be paid to the importance of L-lysine metabolism in those with depression and anxiety.https://doi.org/10.1186/s13099-024-00601-3DepressionAnxietyElastic net analysisN-ε-acetyllysineOdoribacter |
| spellingShingle | Juntaro Matsuzaki Shunya Kurokawa Chiaki Iwamoto Katsuma Miyaho Akihiro Takamiya Chiharu Ishii Akiyoshi Hirayama Kenji Sanada Shinji Fukuda Masaru Mimura Taishiro Kishimoto Yoshimasa Saito Intestinal metabolites predict treatment resistance of patients with depression and anxiety Gut Pathogens Depression Anxiety Elastic net analysis N-ε-acetyllysine Odoribacter |
| title | Intestinal metabolites predict treatment resistance of patients with depression and anxiety |
| title_full | Intestinal metabolites predict treatment resistance of patients with depression and anxiety |
| title_fullStr | Intestinal metabolites predict treatment resistance of patients with depression and anxiety |
| title_full_unstemmed | Intestinal metabolites predict treatment resistance of patients with depression and anxiety |
| title_short | Intestinal metabolites predict treatment resistance of patients with depression and anxiety |
| title_sort | intestinal metabolites predict treatment resistance of patients with depression and anxiety |
| topic | Depression Anxiety Elastic net analysis N-ε-acetyllysine Odoribacter |
| url | https://doi.org/10.1186/s13099-024-00601-3 |
| work_keys_str_mv | AT juntaromatsuzaki intestinalmetabolitespredicttreatmentresistanceofpatientswithdepressionandanxiety AT shunyakurokawa intestinalmetabolitespredicttreatmentresistanceofpatientswithdepressionandanxiety AT chiakiiwamoto intestinalmetabolitespredicttreatmentresistanceofpatientswithdepressionandanxiety AT katsumamiyaho intestinalmetabolitespredicttreatmentresistanceofpatientswithdepressionandanxiety AT akihirotakamiya intestinalmetabolitespredicttreatmentresistanceofpatientswithdepressionandanxiety AT chiharuishii intestinalmetabolitespredicttreatmentresistanceofpatientswithdepressionandanxiety AT akiyoshihirayama intestinalmetabolitespredicttreatmentresistanceofpatientswithdepressionandanxiety AT kenjisanada intestinalmetabolitespredicttreatmentresistanceofpatientswithdepressionandanxiety AT shinjifukuda intestinalmetabolitespredicttreatmentresistanceofpatientswithdepressionandanxiety AT masarumimura intestinalmetabolitespredicttreatmentresistanceofpatientswithdepressionandanxiety AT taishirokishimoto intestinalmetabolitespredicttreatmentresistanceofpatientswithdepressionandanxiety AT yoshimasasaito intestinalmetabolitespredicttreatmentresistanceofpatientswithdepressionandanxiety |